Search

Your search keyword '"Gay, C.M."' showing total 13 results
Start Over Author "Gay, C.M."
13 results on '"Gay, C.M."'

1. 115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC

Author

Reck, M., primary, Nadal, E., additional, Girard, N., additional, Filippi, A.R.R., additional, Martin, L.W., additional, Gay, C.M., additional, Petersen, C., additional, Gale, D., additional, Bridge, H.R., additional, Donner, N., additional, Georgoulia, N.E., additional, and Spicer, J., additional

Published
2023
Full Text
View/download PDF

2. Patterns of Failure by Driver Mutation Status for Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation and Consolidative Durvalumab

Author

Liu, Y., primary, Zhang, Z., additional, Rinsurongkawong, W., additional, Gay, C.M., additional, Lewis, J., additional, Rinsurongkawong, V., additional, Lee, J.J., additional, Lee, P., additional, Zhang, J., additional, Gibbons, D.L., additional, Vaporciyan, A.A., additional, Heymach, J., additional, and Lin, S.H., additional

Published
2022
Full Text
View/download PDF

4. MA01.03 Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach

Author

Heeke, S., primary, Gay, C.M., additional, Estecio, M.R., additional, Stewart, A., additional, Tran, H., additional, Zhang, B., additional, Tang, X., additional, Raso, M.G., additional, Concannon, K., additional, De Sousa, L. Guimaraes, additional, Lewis, W.E., additional, Kondo, K., additional, Nilsson, M.B., additional, Xi, Y., additional, Diao, L., additional, Wang, Q., additional, Zhang, J., additional, Wang, J., additional, Wistuba, I.I., additional, Byers, L.A., additional, and Heymach, J.V., additional

Published
2022
Full Text
View/download PDF

5. 163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial

Author

Della Corte, C.M., primary, Fasano, M., additional, Ciaramella, V., additional, Cimmino, F., additional, Cardnell, R., additional, Gay, C.M., additional, Ramkumar, K., additional, Diao, L., additional, Di Liello, R., additional, Viscardi, G., additional, Famiglietti, V., additional, Ciardiello, D., additional, Martini, G., additional, Napolitano, S., additional, Troiani, T., additional, Martinelli, E., additional, Wang, J., additional, Byers, L., additional, Morgillo, F., additional, and Ciardiello, F., additional

Published
2022
Full Text
View/download PDF

9. Comparison of Severe Toxicities and Survival Between Passive Scattering (PSPT) and Intensity Modulated Protons (IMPT) for NSCLC Patients Treated with Concurrent Chemoradiation

Author

Liao, Z., primary, Xu, T., additional, Elhammali, A., additional, Chun, S.G., additional, Gandhi, S., additional, Lee, P., additional, Chen, A.B., additional, Lin, S.H., additional, Chang, J.Y., additional, Tsao, A., additional, Gay, C.M., additional, Zhu, X.R., additional, Zhang, X., additional, Heymach, J., additional, Fossella, F.V., additional, Lu, C., additional, and Nguyen, Q.N., additional

Published
2020
Full Text
View/download PDF

10. Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

Author

Della Corte, C.M., primary, Ajpacaja, L., additional, Cardnell, R.J., additional, Gay, C.M., additional, Wang, Q., additional, Shen, L., additional, Ramkumar, K., additional, Stewart, A.C., additional, Fan, Y.-H., additional, Adelman, C.A., additional, Travers, J., additional, Wang, J., additional, Heymach, J., additional, and Byers, L.A., additional

Published
2019
Full Text
View/download PDF

11. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

Author

Rustgi, A.K., Cherniack, A.D., Weinstein, J.N., Stuart, J.M., Bowlby, R., Diao, L., Gevaert, O., Schultz, A., The Cancer Genome Atlas Research Network, Taylor, A.M., Walter, V., Lazar, A.J., Chen, J., Flores, E.R., Hoadley, K.A., Laird, P.W., Sadeghi, S., Yau, C., Drill, E., Cheng, H., Anur, P., Mungall, K.L., Tsai, K.Y., Zuna, R., Gunaratne, P., Donehower, L., Chen, Z., Gay, C.M., Pickering, C.R., Van Waes, C., Coarfa, C., Wang, C., Peto, M., Ojesina, A.I., Hegde, A., Shen, R., Pedamallu, C.S., Liu, Y., Shih, J., Wong, C.K., Prunello, M., Kanchi, R.S., Wang, J., Al-Ahmadie, H., Chiu, H.-S., Zhou, J.H., Akbani, R., Brennan, K., Shen, H., Ma, W., Benz, C., Sumazin, P., Fan, H., Hayes, D.N., Byers, L.A., Bullman, S., Campbell, J.D., Rader, J.S., Robertson, A.G., Creighton, C.J., and Chen, T.-W.

Subjects
Epithelial-Mesenchymal Transition, Medical Physiology, Cancer Genome Atlas Research Network, head and neck squamous cell carcinoma, Cell Line, transcriptomics, proteomics, Genetic, genomics, lung squamous cell carcinoma, Genetics, Humans, 2.1 Biological and endogenous factors, Polymorphism, Aetiology, human papillomavirus, Cancer, Neoplastic, Tumor, Carcinoma, Human Genome, bladder carcinoma with squamous differentiation, DNA Methylation, esophageal squamous cell carcinoma, stomatognathic diseases, Squamous Cell, Gene Expression Regulation, cervical squamous cell carcinoma, Sexually Transmitted Infections, Biochemistry and Cell Biology, Metabolic Networks and Pathways, Biotechnology
Abstract

This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or aberrant methylation of genes and microRNAs, which are correlated with the expression of multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal differentiation, growth, genomic integrity, oxidative damage, death, and inflammation. Low-CNA SCCs tended to be HPV(+) and display hypermethylation with repression of TET1 demethylase and FANCF, previously linked to predisposition to SCC, or harbor mutations affecting CASP8, RAS-MAPK pathways, chromatin modifiers, and immunoregulatory molecules. We uncovered hypomethylation of the alternative promoter that drives expression of the ��Np63 oncogene and embedded miR944. Co-expression of immune checkpoint, T-regulatory, and Myeloid suppressor cells signatures may explain reduced efficacy of immune therapy. These findings support possibilities for molecular classification and therapeutic approaches. Campbell et al. reveal that squamous cell cancers from different tissue sites may be distinguished from other cancers and subclassified molecularly by recurrent alterations in chromosomes, DNA methylation, messenger and microRNA expression, or by mutations. These affect squamous cell pathways and programs that provide candidates for therapy.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results